Fueling metabolic disruption via FMD to boost chemotherapy in TNBC.
other
Where this comes from
- Record sourced from PubMed, PMID 39908983.
- Also identified by DOI 10.1016/j.cmet.2024.12.015.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Triple-negative breast cancer (TNBC) is highly glycolytic and lacks effective biomarkers for therapy response. The BREAKFAST trial showed that a fasting-mimicking diet (FMD) improved pathological complete response (pCR) rates to 56.6% compared to historical chemotherapy averages (30%-40%), with minimal severe adverse events. FMD's metabolic and immune-modulating effects warrant further study with immunotherapy.
Medical subject headings
- Triple Negative Breast Neoplasms
- Fasting
- Antineoplastic Agents